1. Endometrial stromal sarcoma: a population-based analysis.
- Author
-
Chan, JK, Kawar, NM, Shin, JY, Osann, K, Chen, L-M, Powell, CB, and Kapp, DS
- Subjects
Humans ,Sarcoma ,Endometrial Stromal ,Endometrial Neoplasms ,Prognosis ,SEER Program ,Age Factors ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Female ,Kaplan-Meier Estimate ,endometrial stromal sarcoma ,prognostic factors ,survival ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
To determine independent prognostic factors for the survival of patients with endometrial stromal sarcoma (ESS), data were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute from 1988 to 2003. Kaplan-Meier and Cox proportional hazards models were used for analyses. Of 831 women diagnosed with ESS, the median age was 52 years (range: 17-96 years). In total, 59.9% had stage I, 5.1% stage II, 14.9% stage III, and 20.1% had stage IV disease. Overall, 13.0, 36.1, and 34.7% presented with grades 1, 2, and 3, respectively. Patients with stage I-II vs III-IV disease had 5 years DSS of 89.3% vs 50.3% (P
- Published
- 2008